Infliximab therapy modulates an antigen-specific immune response in chronic beryllium disease

Respir Med. 2012 Dec;106(12):1810-3. doi: 10.1016/j.rmed.2012.08.014. Epub 2012 Sep 11.
No abstract available

Publication types

  • Letter
  • Randomized Controlled Trial
  • Research Support, N.I.H., Extramural

MeSH terms

  • Aged
  • Anti-Inflammatory Agents, Non-Steroidal / therapeutic use*
  • Antibodies, Monoclonal / therapeutic use*
  • Berylliosis / drug therapy*
  • Berylliosis / immunology
  • Chronic Disease
  • Double-Blind Method
  • Female
  • Humans
  • Immunity, Cellular / drug effects
  • Infliximab
  • Male
  • Middle Aged
  • Quality of Life

Substances

  • Anti-Inflammatory Agents, Non-Steroidal
  • Antibodies, Monoclonal
  • Infliximab

Associated data

  • ClinicalTrials.gov/NCT00111917